{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(24)"],"submitter":["Li Z"],"pubmed_abstract":["<h4>Background</h4>Squamous cell carcinoma (SCC) and adenocarcinoma (AC) are the two main pathological types of esophageal cancer (EC), which differ in molecular features, genetic variation, and treatment sensitivity. However, as a key process in tumorigenesis and development, the role of N6-methyladenosine (m6A) regulators in esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) is not fully understood.<h4>Methods</h4>This study systematically compared the role of m6A regulators of ESCC and EAC in terms of molecular characteristics, immuno-oncology characteristics, and clinical relevance, and validated our findings in a long-term follow-up patient cohort.<h4>Results</h4>There were many differences in m6A regulators between ESCC and EAC in terms of expression patterns, genetic variation, association with tumor pathways, immune signatures, and immunotherapy sensitivity. Furthermore, <i>VIRMA</i> was identified as a factor with opposite functional and prognostic effects in ESCC and EAC. ESCC patients with high <i>VIRMA</i> expression and EAC patients with low <i>VIRMA</i> expression had a better prognosis. Single-center data showed that low expression of <i>FTO</i> may be associated with superior immunotherapy efficacy in ESCC patients.<h4>Conclusions</h4>The results herein provide novel ideas for understanding the tumor characteristics, occurrence, and development of ESCC and EAC, and suggest new targets for the treatment and intervention of EC."],"journal":["Annals of translational medicine"],"pagination":["1347"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9843396"],"repository":["biostudies-literature"],"pubmed_title":["The landscape of m6A regulators in esophageal cancer: molecular characteristics, immuno-oncology features, and clinical relevance."],"pmcid":["PMC9843396"],"pubmed_authors":["Yin X","Li Z","Zheng C","Huang L","Liu C","Li B","Wang Z"],"additional_accession":[]},"is_claimable":false,"name":"The landscape of m6A regulators in esophageal cancer: molecular characteristics, immuno-oncology features, and clinical relevance.","description":"<h4>Background</h4>Squamous cell carcinoma (SCC) and adenocarcinoma (AC) are the two main pathological types of esophageal cancer (EC), which differ in molecular features, genetic variation, and treatment sensitivity. However, as a key process in tumorigenesis and development, the role of N6-methyladenosine (m6A) regulators in esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) is not fully understood.<h4>Methods</h4>This study systematically compared the role of m6A regulators of ESCC and EAC in terms of molecular characteristics, immuno-oncology characteristics, and clinical relevance, and validated our findings in a long-term follow-up patient cohort.<h4>Results</h4>There were many differences in m6A regulators between ESCC and EAC in terms of expression patterns, genetic variation, association with tumor pathways, immune signatures, and immunotherapy sensitivity. Furthermore, <i>VIRMA</i> was identified as a factor with opposite functional and prognostic effects in ESCC and EAC. ESCC patients with high <i>VIRMA</i> expression and EAC patients with low <i>VIRMA</i> expression had a better prognosis. Single-center data showed that low expression of <i>FTO</i> may be associated with superior immunotherapy efficacy in ESCC patients.<h4>Conclusions</h4>The results herein provide novel ideas for understanding the tumor characteristics, occurrence, and development of ESCC and EAC, and suggest new targets for the treatment and intervention of EC.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-04-04T08:29:25.347Z","creation":"2025-04-04T08:29:25.347Z"},"accession":"S-EPMC9843396","cross_references":{"pubmed":["36660671"],"doi":["10.21037/atm-22-5895"]}}